SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
Active, not recruiting · NCT04803877 · Registry updated 2025-10-31Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma | Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, neoplasm, osteosarcoma, sarcoma | Active, not recruiting | Phase 2 | 2025-10-31 | NCT04803877 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Sarcoma Alliance for Research through Collaboration | 7 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Children's Hospital of Los Angeles | Los Angeles | United States | 56 |
| Cincinnati Children's | Cincinnati | United States | 5 |
| Johns Hopkins | Baltimore | United States | 39 |
| Oregon Health and Sciences University | Portland | United States | 20 |
| University of Miami | Miami | United States | 327 |
| University of Michigan | Ann Arbor | United States | 538 |
| University of Minnesota | Minneapolis | United States | 325 |
| UT Southwestern Medical Center | Dallas | United States | 210 |